Quantifying comorbidity in individuals with COPD: A population study

European Respiratory Journal

Volumn 45, Issue 1, 2015, Pages 51-59

  Gershon, Andrea S ^a,b,c,d   Mecredy, Graham C ^b   Guan, Jun ^b   Victor, J Charles ^b,c   Goldstein, Roger ^c,e   To, Teresa ^b,c,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e West Park Healthcare Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMBULATORY CARE; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; EMERGENCY HEALTH SERVICE; FEMALE; FRACTURE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; LOWER RESPIRATORY TRACT INFECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEOPLASM; POPULATION RESEARCH; AGED; COMPLICATION; LUNG TUMOR; MIDDLE AGED; ONTARIO; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ADULT; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES COMPLICATIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MENTAL DISORDERS; MIDDLE AGED; MODELS, STATISTICAL; MUSCULOSKELETAL DISEASES; NEOPLASMS; ONTARIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84920557583     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00061414     Document Type: Article

References (38)

1. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013; 1: 73-83.
2. Agusti A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2012; 9: 43-46.
3. Burgel PR, Escamilla R, Perez T, et al. Impact of comorbidities on COPD-specific health-related quality of life. Respir Med 2012; 107: 233-241.
4. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
5. Gershon AS, Guan J, Victor JC, et al. Quantifying health services use for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 596-601.
6. Liapikou A, Polverino E, Ewig S, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012; 39: 855-861.
7. Rabe KF, Wedzicha JA, Wouters EFM. COPD and Comorbidity. ERS Monogr 2013; 59.
8. Boutin-Forzano S, Moreau D, Kalaboka S, et al. Reported prevalence and co-morbidity of asthma, chronic bronchitis and emphysema: a pan-European estimation. Int J Tuberc Lung Dis 2007; 11: 695-702.
9. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-962.
10. Li L, Brennan KJ, Gaughan JP, et al. African Americans and men with severe COPD have a high prevalence of osteoporosis. COPD 2008; 5: 291-297.
11. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
12. Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010; 35: 1209-1215.
13. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099-2107.
14. Gershon AS, Wang C, Guan J, et al. Identifying individuals with physician diagnosed COPD in health administrative databases. J COPD 2009; 6: 388-394.
15. Gershon AS, Warner L, Cascagnette P, et al. Lifetime risk of developing chronic obstructive pulmonary disease (COPD). Lancet 2011; 378: 991-996.
16. PCCF+ Version 4D User's Guide (Geocodes/PCCF). Automated Geographic Coding Based on the Statistics Canada Postal Code Conversion Files, Including Postal Codes to December 2003. Ottawa, Statistics Canada, 2004.
17. Plessis V, Beshiri R, Bollman R, et al. Definitions of "Rural". Ottawa, Statistics Canada, 2002
18. Gershon AS, Wang C, Vasilevska-Ristovska J, et al. Identifying patients with physician diagnosed asthma in health administrative databases. Can Respir J 2009; 16: 183-188.
19. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997; 16: 791-801.
20. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303.
21. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122: 348-355.
22. Garcia-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC Fam Pract 2013; 14: 11.
23. Garcia Rodriguez LA, Wallander MA, Martin-Merino E, et al. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med 2010; 104: 1691-1699.
24. Joo H, Park J, Lee SD, et al. Comorbidities of chronic obstructive pulmonary disease in Koreans: a population-based study. J Korean Med Sci 2012; 27: 901-906.
25. Kornum JB, Svaerke C, Thomsen RW, et al. Chronic obstructive pulmonary disease and cancer risk: a Danish nationwide cohort study. Respir Med 2012; 106: 845-852.
26. Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med 2010; 104: 697-704.
27. Ng TP, Niti M, Fones C, et al. Co-morbid association of depression and COPD: a population-based study. Respir Med 2009; 103: 895-901.
28. Schneider C, Bothner U, Jick SS, et al. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010; 25: 253-260.
29. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012; 12: 26.
30. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of overspill of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010; 65: 930-936.
31. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179-191.
32. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008; 15: Suppl. A, 1A-8A.
33. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD, 2013.
34. Cleland JA, Lee AJ, Hall S. Associations of depression and anxiety with gender, age, health-related quality of life and symptoms in primary care COPD patients. Fam Pract 2007; 24: 217-223.
35. Offord DR, Boyle MH, Campbell D, et al. One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age. Can J Psychiatry 1996; 41: 559-563.
36. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
37. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523-532.
38. Gershon AS, Hwee J, Croxford R, et al. Patient and physician factors associated with pulmonary function testing for COPD: a population study. Chest 2014; 145: 272-281.